MGMT and central nervous system cancer: In recent years, with the rapid development of the molecular pathology of glioma, a series of molecular markers, such as IDH mutation, 1p/19q codeletion, and MGMT methylation status, have been considered to be related to the malignancy of glioma and patient prognosis.